Locally Advanced Pancreatic Adenocarcinoma Clinical Trial
Official title:
Exploratory Trial of Immunochemoradiotherapy for Locally Advanced Pancreatic Adenocarcinoma
This study will add an immunotherapy component to chemotherapy and radiation treatment in patients who have pancreatic cancer. The objective of this study is to see if the combined treatment is safe and feasible, and if a larger study is warranted.
All study participants receive an initial 4 week course of intra-dermal vaccination with
telomerase vaccine (GV1001) and immune adjuvant, granulocyte macrophage colony-stimulating
factor (GM-CSF), along with a cycle of gemcitabine chemotherapy. This is followed by
concurrent radiation therapy and low-dose intravenous (IV) gemcitabine chemotherapy given
twice weekly followed by one additional dose of vaccine.
About 4 weeks (as late as 8 weeks) after chemotherapy and radiation treatment, participants
with disease that can be removed by surgery will proceed to surgery. After recovery,
immunochemotherapy will resume.
Participants with stable or responsive disease that is not able to be treated with surgery
will proceed to immunochemotherapy.
Immunochemotherapy will consist of 2 cycles of telomerase vaccine with GM-CSF along with
gemcitabine chemotherapy. Participants with disease that is not able to be treated with
surgery, or that has worsened following immunochemoradiotherapy phase of treatment may
continue on study with transition to immunochemotherapy phase of treatment. Tadalafil will be
administered orally on a daily basis from start of therapy (Day 1) through completion of
therapy with doses held only when required in the immediate perioperative period in patients
who proceed to surgery.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05679674 -
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
|
N/A | |
| Recruiting |
NCT04617821 -
AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer
|
Phase 3 | |
| Completed |
NCT03673137 -
Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04652206 -
Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
|
Phase 1/Phase 2 | |
| Completed |
NCT02394535 -
Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06399172 -
OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy
|
||
| Withdrawn |
NCT03536182 -
Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT04395469 -
FAZA PET/MRI Pancreas
|
N/A | |
| Active, not recruiting |
NCT01585805 -
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT05607953 -
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
|
Phase 1 | |
| Not yet recruiting |
NCT06381154 -
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03269526 -
BATs Treatment for Pancreatic Cancer, Phase Ib/II
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06453486 -
A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment
|
Phase 2 | |
| Recruiting |
NCT05524090 -
PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer
|
||
| Completed |
NCT01278368 -
Effect Of Preoperative Chemotherapy On Short-Term Outcome After Pancreatic Resection
|
N/A | |
| Recruiting |
NCT04172532 -
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04423731 -
Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer
|
||
| Not yet recruiting |
NCT06272162 -
Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy
|
N/A | |
| Active, not recruiting |
NCT00669734 -
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
|
Phase 1 | |
| Recruiting |
NCT04665947 -
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
|
Early Phase 1 |